Cynthia Brinson

4.9k citations

36 papers · 1.5k indexed · 1 hit paper · h-index 18

Virology top 0.5%
- HIV Research and Treatment 27
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment 34
- HIV/AIDS Research and Interventions 17
Emergency Medicine top 1%
- HIV-related health complications and treatments 12
Hepatology top 5%
- Hepatitis C virus research 6
Epidemiology top 10%
- Pneumocystis jirovecii pneumonia detection and treatment 4
Genetics
- Chronic Lymphocytic Leukemia Research 2
Molecular Biology
- Biochemical and Molecular Research 1

Co-authors: Andrew Cheng Anthony Mills Brian Wynne Edwin DeJesus Michael Aboud Hal Martin Melanie Thompson Kati Vandermeulen
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: Open Forum Infectious Diseases (8 papers)The Lancet HIV (5 papers)AIDS (3 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Cynthia Brinson

33 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Cynthia Brinson

Since Specialization

Citations

This map shows the geographic impact of Cynthia Brinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cynthia Brinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cynthia Brinson more than expected).

Fields of papers citing papers by Cynthia Brinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cynthia Brinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cynthia Brinson. The network helps show where Cynthia Brinson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Cynthia Brinson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Cynthia Brinson Line = papers co-authored together Cynthia Brinson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study Medicine ·Indira Brar,Peter Ruane,Mezgebe Berhe,Cynthia Brinson,Paul Benson,Keith Henry,Hui Liu,Kristen Andreatta,Jason T. Hindman,Moti Ramgopal	2025	0
2	Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV AIDS Research and Therapy ·Eric S. Daar,Chloe Orkin,Paul E. Sax,Debbie Hagins,Anton Pozniak,Kimberly Workowski,Cynthia Brinson,Juan Tiraboschi,Hui Liu,Denise Anne Mosher,Cal Cohen,Sharline Madera,Jason T. Hindman,Moti Ramgopal	2025	0
3	Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab The Journal of Infectious Diseases ·Joseph J. Eron,Paul Cook,Megha Mehrotra,Hailin Huang,Marina Caskey,近夫奥田,Linda Gorgos,Laurie A. VanderVeen,AG Engel,Sean E Collins,Olayemi Osiyemi,Cynthia Brinson,Edwin DeJesus	2025	1
4	1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine Open Forum Infectious Diseases ·Indira Brar,Peter Ruane,Douglas Ward,Jean‐Michel Molina,Anthony Mills,Mezgebe Berhe,Cynthia Brinson,Chenghua Hiu,Paul Benson,Keith Henry,Hailin Huang,Kristen Andreatta,Hal Martin	2020	3
5	Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet HIV ·David A. Wohl,Yazdan Yazdanpanah,Axel Baumgarten,Amanda Clarke,Melanie Thompson,Cynthia Brinson,Debbie Hagins,Moti Ramgopal,Andrea Antinori,Xuelian Wei,Rima Acosta,Sean E Collins,Diana M. Brainard,Hal Martin	2019	116
6	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesbreakdown → The Lancet ·Josep M. Llibre,Chien‐Ching Hung,Cynthia Brinson,Francesco Castelli,Pierre‐Marie Girard,Lesley Kahl,Elizabeth A. Blair,شهریار نیازی,Brian Wynne,Kati Vandermeulen,Mark Underwood,Guijun Xian,Martin Gartland,Michael Aboud	2018	243
7	Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide AIDS ·Paul E. Sax,Edwin DeJesus,Gordon Crofoot,Douglas Ward,Paul Benson,Robin Dretler,Anthony Mills,Cynthia Brinson,Xuelian Wei,Sean E Collins,Andrew Cheng	2018	7
8	Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial The Lancet HIV ·Jean‐Michel Molina,Douglas Ward,Indira Brar,Anthony Mills,Hans‐Jürgen Stellbrink,Luís F. López‐Cortés,Peter Ruane,Daniel Podzamczer,Cynthia Brinson,Joseph M. Custodio,Hui Liu,Kristen Andreatta,Hal Martin,Andrew Cheng,Erin Quirk	2018	138
9	Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial The Lancet HIV ·Paul E. Sax,Edwin DeJesus,Gordon Crofoot,Douglas Ward,Paul Benson,Robin Dretler,Anthony Mills,Cynthia Brinson,Salim Zahoueh,Xuelian Wei,Kirsten White,Andrew Cheng,Hal Martin,Erin Quirk	2017	72
10	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial The Lancet HIV ·Joel E. Gallant,Eric S. Daar,François Raffi,Cynthia Brinson,Peter Ruane,Edwin DeJesus,Margaret Johnson,Nathan Clumeck,Olayemi Osiyemi,J. Z. Zhu,Javier O Morales-Ramirez,Mingjin Yan,Michael E. Abram,Andrew Plummer,Andrew Cheng,Martin S. Rhee	2016	127
11	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial The Lancet Infectious Diseases ·David A. Margolis,Cynthia Brinson,Graham Smith,Jerome De Vente,Debbie Hagins,Joseph J. Eron,Sandy Griffith,M H St Clair,Marita Stevens,Peter Williams,Susan L. Ford,Britt Stancil,Linn T. E. Orre,Krischan J Hudson,Kimberly Y. Smith,William Spreen	2015	157
12	Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment AIDS Care ·Michael Arndell,Calvin Cohen,Benoît Trottier,Stefan Eßer,Don Smith,Bernhard Haas,Cynthia Brinson,Will Garner,Susan K. Chuck,David Thorpe,Shampa De-Oertel	2015	17
13	Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial The Lancet HIV ·Jacob Lalezari,Gulam Latiff,Cynthia Brinson,Juan Echevarría,Wilda Ulya,Johannes R. Bogner,Melanie Thompson,Jan Fourie,Joshua Lane,H Delonca,Marcelo Martins,Marcus J Byrd,David Stock,Samit R. Joshi,George J. Hanna,Max Lataillade	2015	50
14	The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects HIV Medicine ·Fred Schäfer,Cynthia Brinson,Moti Ramgopal,Robert J. Ryan,Bruce Coate,Malek,Thomas N. Kakuda,David Anderson	2015	13
15	Safety profile of HIV‐1 attachment inhibitor prodrug BMS‐663068 in antiretroviral‐experienced subjects: week 24 analysis Journal of the International AIDS Society ·Jacob Lalezari,Gulam Latiff,Cynthia Brinson,Juan Echevarría,Wilda Ulya,Johannes R. Bogner,David Stock,Samit R. Joshi,George J. Hanna,Max Lataillade	2014	4
16	Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine The Journal of Infectious Diseases ·Marshall J. Glesby,Wendy Watson,Cynthia Brinson,Richard N. Greenberg,Jacob Lalezari,Daniel J. Skiest,Vani Sundaraiyer,Robert J. Natuk,Alejandra Gurtman,Daniel A. Scott,Emilio A. Emini,William C. Gruber,Beate Schmöele-Thoma	2014	43
17	Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data HIV Clinical Trials ·Anthony Mills,Gordon Crofoot,Roberto Ortiz,Bruce Rashbaum,William Towner,Derek Ward,Cynthia Brinson,Rohan Kulkarni,Cyrille Roget,Ramin Ebrahimi,H. Cao,Andrew Cheng,Javier Szwarcberg	2014	17
18	Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens HIV Clinical Trials ·Anthony Mills,Calvin Cohen,Edwin DeJesus,Cynthia Brinson,Scott Williams,Kitty Yale,Srini Ramanathan,Maggie Haitian Wang,Kirsten White,Susan K. Chuck,Andrew Cheng	2013	61
19	SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen Clinical Infectious Diseases ·Rafael Campo,E DeJesus,U. Fritz Bredeek,Keith Henry,Homayoon Khanlou,何力佳,Cynthia Brinson,Paul Benson,S. J. Andrews,Seoung Yoon Shin,Kirsten White,John F. Flaherty,Todd Fralich,Bill Guyer,David Piontkowsky	2013	36
20	Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jacob Lalezari,Joseph Gathe,Cynthia Brinson,Melanie Thompson,Calvin Cohen,Edwin DeJesus,Ana Gamarra Carrasco,Jerome Ernst,David E. Martin,Dedy Achmad Kurniady Et al.	2011	56

About Cynthia Brinson

Cynthia Brinson is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 36 papers that have together received 1.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (34 papers), HIV Research and Treatment (27 papers), HIV/AIDS Research and Interventions (17 papers), HIV-related health complications and treatments (12 papers), Hepatitis C virus research (6 papers), Pneumocystis jirovecii pneumonia detection and treatment (4 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Biochemical and Molecular Research (1 paper). The work is most often cited by research in Virology (1.0k citations), Infectious Diseases (1.3k citations) and Emergency Medicine (449 citations). Cynthia Brinson has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Andrew Cheng, Anthony Mills, Brian Wynne, Edwin DeJesus, Michael Aboud, Hal Martin, Melanie Thompson, Kati Vandermeulen, Peter Ruane and Debbie Hagins. Their work appears in journals such as Open Forum Infectious Diseases, The Lancet HIV, AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes and HIV Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact